Skip to main content

Bipolar Disorders

A study recently published in BMC Psychiatry found that antipsychotic dosage reduction in patients with bipolar and major depressive disorders was associated with an increase in all-cause and mental health-related hospitalizations.
What criteria differentiates between bipolar disorder with psychotic features and the bipolar type of schizoaffective disorder?
In this video, Christoph U. Correll, MD, of Hofstra/Northwell in New York, discusses the possible clinical applications of the combination of olanzapine and the mu-opioid antagonist samidorphan.
Christoph U. Correll, MD, discusses the results of the ENLIGHTEN‑2 study, which compared weight gain and cardiometabolic side effects in patients taking olanzapine and patients taking olanzapine plus samidorphan.
The US Food and Drug Administration (FDA) has accepted Alkermes’ New Drug Application (NDA) for ALKS 3831, a combination of olanzapine and samidorphan, the company announced.
Back to Top